Doctors Share How They Use DCISionRT in Clinic

  • DCIS Biopsy Case Studies: Surgeon Roundtable

    Presented by: Leona Hamrick, DHSc, PA-C, MSL-BC, Steven Cai, MD, FACS, Lynn Canavan, MD, FACS, Pat Whitworth, MD, FACS

    Click the chapter icon on the player to search discussion topics.

    Leona Hamrick, DHSc, PA-C, MSL-BC

    Senior Director of Global Medical Affairs, PreludeDx

    0:00 Welcome & Speaker Introductions
    1:30 DCISionRT Validation Data Review

    Pat Whitworth, MD, FACS

    Breast Surgical Oncology Specialist, Director of the Nashville Breast Cancer

    16:56 Core Biopsy Case Studies

    Lynn Canavan, MD, FACS

    Medical Director of Breast Surgical Oncology, Texas Breast Specialists

    28:43 Core Biopsy Case Studies & Practice Comparison

    Steven Cai, MD, FACS

    Director of Surgical Services, Rendr Care, and Clinical Assistant Professor at Mount Sinai Icahn School of Medicine

    42:26 Core-Biopsy Case Studies

    Leader of Breast Cancer Multidisciplinary Team, Comprehensive Breast Care, A Division of Michigan Healthcare Professionals

    Roundtable Discussion:

    55:41 Closing Thoughts
    59:01 Endocrine Therapy
    1:01:45 Ordering DCISionRT when Cancer may be Invasive
    1:05:05 DCISionRT’s Residual Risk Group
    1:05:35 DCISionRT Turnaround Time

  • DCIS Case Studies: Surgeon Roundtable

    Presented by: Troy Bremer, PhD, Leona Hamrick, DHSc, PA-C, MSL-BC, Erica Giblin, MD, James Pellicane, MD, Eric Brown, MD, FACS

    Click the chapter icon on the player to search discussion topics.

    Troy Bremer, PhD

    Founder & Chief Scientific Officer of PreludeDx

    0:00 Welcome & Speaker Introductions
    0:59 Identifying Patient Risk with DCISionRT
    6:51 DCISionRT Validation Data Review

    Leona Hamrick, DHSc, PA-C, MSL-BC

    Senior Director, Global Medical Affairs, PreludeDx

    16:25 Comparing Validation Data & Clinical Results

    James Pellicane, MD

    Director of Breast Oncology, Bon Secours Cancer Institute

    20:09 Real-world RRt Case Studies

    Erica Giblin, MD

    Medical Director of Breast Care Services, Breast Surgical Oncologist, Ascension Medical Group

    30:32 Real-world RRt Case Studies

    Eric Brown, MD, FACS

    Leader of Breast Cancer Multidisciplinary Team, Comprehensive Breast Care, A Division of Michigan Healthcare Professionals

    38:18 Real-world RRt Case Studies

    Surgeon Roundtable Discussion:

    45:23 Core Biopsy vs. Surgical Specimen
    48:40 Oncoplastic Considerations
    50:03 DCISionRT Specimen Requirements
    51:10 Insurance and Turnaround Time
    51:56 Radiation Therapy Considerations
    54:39 Integrating DCISionRT in Clinical Workflow
    55:21 Role of Radiation Therapy

  • DCIS Case Studies: Radiation Oncologist Roundtable

    Presented by: Troy Bremer, PhD, Leona Hamrick, DHSc, PA-C, MSL-BC, Chirag Shah, MD, Fleure Gallant, MD, and Lonika Majithia, MD

    Click the chapter icon on the player to search discussion topics.

    Troy Bremer, PhD

    Founder & Chief Scientific Officer of PreludeDx

    0:00 Welcome & Speaker Introductions

    Leona Hamrick, DHSc, PA-C, MSL-BC

    Senior Director, Global Medical Affairs, PreludeDx

    1:15 Identifying Patient Risk with DCISionRT

    Troy Bremer, PhD

    Founder & Chief Scientific Officer of PreludeDx

    8:46 DCISionRT Validation Data Review

    Leona Hamrick, DHSc, PA-C, MSL-BC

    Senior Director, Global Medical Affairs, PreludeDx

    17:32 Comparing Clinical Results with Validation Data

    Chirag Shah, MD

    Co-Director of Comprehensive Breast Program and Director of Clinical Research in the Department of Radiation Oncology at the Cleveland Clinic

    20:26 Real-world RRt Case Studies—High Grade Patients

    Fleure Gallant, MD

    Clinical Director of Radiation Oncology, Maimonides Medical Center. Clinical Assistant Professor, SUNY Downstate Medical Center

    25:32 Real-world RRt Case Studies—Varying HR Status and Age

    Lonika Majithia, MD

    Medical Director of Brachytherapy & Director of Radiation Oncology Educational Program at Inova Schar Cancer Center

    35:00 Real-world RRt Case Studies—Varying HR Status and Age

    Radiation Oncologist Roundtable Discussion:

    42:00 Patient Risk Tolerance
    44:11 RT Modalities
    49:41 Impact of Nuclear Grade
    52:35 Personal Physician Experience with DCISionRT
    54:15 Mastectomies for Patients with RRt
    56:44 Implication of DCISionRT RRt for Multi-Disciplinary Teams
    1:00:10 Surveilling RRt Patients

  • Identifying DCIS Patients Still at Elevated Risk of Recurrence after Surgery and Radiation – Published in Red Journal

    Presented by: Pat Whitworth, MD, FACS, Troy Bremer, PhD and Chirag Shah, MD

    Click the chapter icon on the player to search discussion topics.

    Pat Whitworth, MD, FACS

    Breast Surgical Oncology Specialist, Director of the Nashville Breast Center

    0:34 Clinical Need–takeaways from DCIS randomized landmark trials, RTOG, NCCN

    Troy Bremer, PhD

    Founder & Chief Scientific Officer of PreludeDx

    5:08 Genomic Solution—DCISionRT
    8:56 Who will recur despite BCS+RT?
    9:42 Pathway for residual recurrence risk
    10:52 About Residual Risk Subtype (RRt)

    Chirag Shah, MD

    Co-Director of Comprehensive Breast Program and Director of Clinical Research in the Department of Radiation Oncology at the Cleveland Clinic

    11:15 Validation data of DCISionRT+RRt
    14:20 Stratification for RT benefit and NNT
    18:20 RRt clinpath subpopulations

    Pat Whitworth, MD, FACS

    Breast Surgical Oncology Specialist, Director of the Nashville Breast Center

    19:05 Validation supporting true low risk and RT benefit groups
    20:43 Age and grade Subpopulation analysis
    23:40 Individualized patient care

    Troy Bremer, PhD

    Founder & Chief Scientific Officer of PreludeDx

    24:00 Summary:  Supportive evidence
    26:22 Real-world Case Studies

    Panel Q and A Discussion

    33:36 Addressing microcalcifications in study cohort
    34:19 Local Recurrence rate vs metastatic rate in study cohort
    35:06 Margins status and DS in study cohort and treatment implications
    37:33 Hormone Receptor status in study cohort and treatment implications
    41:55 Overcoming nuclear grade subjectivity
    43:36 Management of patients meeting RTOG criteria
    44:52 RT modalities
    45:42 Implementing into clinical practice
    48:15 Specimen type for testing
    49:30 RRt vs Decision Score
    50:25 RRt treatment implications
    50:25 Closing statements from KOLs

  • Practical and Effective Implementation of Precision Medicine in Radiation Oncology Pathways for Your DCIS Patients

    Presented by: Troy Bremer, PhD and Rachel Rabinovitch, MD, FASTRO

    Click the chapter icon on the player to search discussion topics.

    Troy Bremer, PhD

    Founder & Chief Scientific Officer of PreludeDx

    0:05 Speaker Introduction and Agenda

    Rachel Rabinovitch, MD, FASTRO

    Radiation Oncologist, Professor, Radiation Oncology, University of Colorado

    1:08 Background DCIS Treatment – Radiation Therapy Landmark Trials

    Troy Bremer, PhD

    Founder & Chief Scientific Officer of PreludeDx

    10:35 Data Overview and Clinical Evidence
    11:20 DCISionRT Test Report
    12:39 Integration of Biology and Clinicopathologic Factors
    16:50 DCISionRT Demonstrates Consistent RT Prediction
    18:20 DCISionRT Correctly Reclassifies ClinPath in All Validation Cohorts
    22:46 Supportive Evidence DCISionRT

    Rachel Rabinovitch, MD, FASTRO

    Radiation Oncologist, Professor, Radiation Oncology, University of Colorado

    24:15 Clinical Application in Radiation Oncology – My Approach to DCIS

    Panel Q and A Discussion

    38:47 Q&A and Discussion
    38:58 Test’s impact on mastectomy decisions
    40:40 Risk assessment by ClinPath
    42:05 Integrating into tumor board and workflow
    42:58 Test’s impact on boost decisions
    44:55 Test’s impact on margins assessment
    51:19 DCISionRT vs OncotypeDCIS
    52:40 ex-US availability
    53:06 Getting started and specimen requirements
    56:55 Test’s impact regarding endocrine therapy

  • Real-world Analysis Results and Application of Precision Medicine in Surgical Practice and Introduction of DCISionRT with Novel Residual Risk Subtype

    Presented by: Troy Bremer, PhD, Julie Margenthaler, MD, FACS and, Chirag Shah, MD

    Click the chapter icon on the player to search discussion topics.

    Troy Bremer, PhD

    Founder & Chief Scientific Officer of PreludeDx

    1:44 Clinical Application of DCISionRT
    4:40 Clinical Evidence

    Julie Margenthaler, MD, FACS

    Breast Surgeon, Siteman Cancer Center, Washington University School of Medicine St Louis, Missouri

    10:30 Patient Discussion and Clinical Application
    13:43 100 Patient Analysis
    20:40 Case Studies

    Troy Bremer, PhD

    Founder & Chief Scientific Officer of PreludeDx

    23:31 DCIS Biosignature Score and Residual Risk Subtype

    Panel Discussion with the Speakers: Multidisciplinary Perspectives – Q/A Discussion

    33:32 Treatment Recommendations for Residual Risk Type
    39:08 Treatment with Endocrine Therapy for patients under 50 years old with a low-risk vs elevated score
    50:54 Additional Ongoing Research – Troy Bremer, PhD
    51:48 Final Thoughts – Julie Margenthaler, MD, FACS and Chirag Shah, MD

    Closing Remarks

    53:13 Closing Remarks from Troy Bremer, PhD

  • Newly Published Data Review of DCISionRT Randomized SweDCIS Results and Clinical Utility for Oncoplastic Surgical Planning

    Presented by: Troy Bremer, PhD, Pat Whitworth, MD, Chirag Shah, MD, Anne Peled, MD, and Karen Barbosa, DO, FACOS

    Click the chapter icon on the player to search discussion topics.

    Troy Bremer, PhD

    Founder & Chief Scientific Officer of PreludeDx

    0:00 Welcome, Introductions, and Agenda
    2:02 Introduction to DCISionRT
    5:58 DCISionRT Validation Data Review

    Pat Whitworth, MD, FACS

    Breast Surgical Oncology Specialist, Director of the Nashville Breast Center

    10:15 Standard of Care for DCIS
    12:06 DCISionRT Correctly Reclassifies Patient Risk
    14:27 Surgical Perspective on Clinical Impact of DCISionRT

    Chirag Shah, MD

    Director of Clinical Research & Associate Professor in the Department of Radiation Oncology at the Cleveland Clinic

    17:46 DCISionRT Helps to Tailor Individual Radiation Treatment Decisions
    20:06 DCISionRT Minimizes Over & Under Treatment
    22:14 Clinical Implications of DCISionRT for Radiation Oncologists

    Anne Peled, MD

    Co-Director, Sutter CPMC Breast Cancer Program

    23:39 Clinical Application of DCISionRT
    27:40 Oncoplastic Case Studies
    33:16 Clinical Considerations & Benefits of DCISionRT

    Karen Barbosa, DO, FACOS

    Breast Surgeon, Oncoplastic Surgeon, & Medical Director of Tidal Health Delaware Breast Cancer Program

    35:38 Incorporating DCISionRT into a Health System

    Panel Discussion

    38:46 What are the important considerations when utilizing DCISionRT?
    41:26 Ordering DCISionRT on lumpectomies & biopsies
    44:07 How to use DCISionRT in your surgical practice
    47:15 How do surgical margins apply to radiation oncology?
    53:47 Endocrine therapy for DCIS
    56:51 Patient risk tolerance

  • Part 2 – Will my Breast Cancer Patient with DCIS Benefit from Radiation after Surgery

    Moderator: Dede Goehler, BSN
    Featured Speakers: Leonard Farber, MD and Beth Dupree, MD, FACS, ABOIM

    Click the chapter icon on the player to search discussion topics.

    Leonard Farber, MD

    • Radiation Oncologist
    • Sr. Clinical Adviser, PreludeDx
    1:34 Current Standard of DCIS Care
    4:34 Clinicopatholgy Alone Doesn’t Accurately Assess Risk
    6:07 DCISionRT – The Predictive DCIS Test
    10:49 Validation Data Review
    18:33 Clinical Utility of DCISionRT
    20:10 Clinical Utility–Radiation Oncologist Perspective

    Beth DuPree, MD, FACS, ABOIM

    Breast Surgeon

    20:54 Clinical Utility- Surgeon Perspective
    28:48 Case Studies
    41:50 Integrating DCISionRT Into Your Practice

    Q and A with the Panelists

    48:07 How can I integrate DCISionRT with the doctors in my practice?
    51:40 Can DCISionRT be used to help guide endocrine therapy?
    54:52 Is DCISionRT covered by insurance?

  • Newly Published Data Review: DCISionRT Randomized SweDCIS Results

    Presented by: Dan Forche, Fredrik Warnberg, MD, PhD, Troy Bremer, PhD, Pat Whitworth, MD, FACS, Chirag Shah, MD, Frank A. Vicini, MD, FACR, FABS, FASTRO, and Bruce Mann, MBBS, PhD, FRACS

    Click the chapter icon on the player to search discussion topics.

    Dan Forche

    President & CEO of PreludeDx

    0:00 Speaker Introductions & Agenda

    Fredrik Warnberg, MD, PhD

    Professor in the Dept. of Surgery, University of Gothenburg, Sweden

    2:09 Rationale for DCISionRT Validation in SweDCIS

    Troy Bremer, PhD

    Founder & Chief Scientific Officer of PreludeDx

    4:39 Summary of DCISionRT Randomized SweDCIS Results

    Pat Whitworth, MD, FACS

    Breast Surgical Oncology Specialist, Director of the Nashville Breast Center

    9:33 Clinical Value beyond Clinpath
    9:33 Decision Impact/Clinical Utility Study Results
    15:15 Surgical Perspective on the Clinical Impact of DCISionRT

    Chirag Shah, MD

    Co-Director of the Comprehensive Breast Program, Cleveland Clinic

    16:32 Consistent Prediction of RT Benefit
    16:32 DCISionRT Risk Stratifies RTOG
    20:42 Clinical Implications of DCISionRT for Radiation Oncologists

    Case Studies

    22:00 Case Studies

    Panel Discussion with the Speakers

    39:19 Standard of Care in Sweden – Fredrik Warnberg, MD, PhD
    40:18 Ordering DCISionRT on a Pre-Surgical Biopsy – Pat Whitworth, MD, FACS
    44:11 The Future of DCISionRT – Troy Bremer, PhD
    47:00 Use of Tamoxifen in Patients with DCIS – Bruce Mann, MBBS, PhD,
    FRACS. Chirag Shah, MD. Frank Vicini, MD, FACR, FASTRO, FABS. Pat Whitworth, MD, FACS.
    50:46 Surgical Margins – Chirag Shah, MD & Pat Whitwoth, MD, FACS

    Q and A with the Panelists

    53:27 Are patients with higher residual risk candidates for mastectomy?
    55:40 How is DCISionRT validated for margin status?
    56:04 Is DCISionRT the “gold standard” of care for DCIS?
    57:38 Biologic Drivers in DCISionRT
    1:00:52 What do DCISionRT’s independent studies look like when combined?
    1:02:28 Confidence when using clinicopathology factors to make decisions

    Closing Remarks

    1:04:00 Closing Remarks from Troy Bremer

  • Clinical Utility of DCISionRT for Oncoplastic Surgical Planning in Patients with DCIS

    Presented by: David Dabbs, MD, Julie Reiland, MD, FACS, and Anne Peled, MD

    Disclaimer: The following video contains graphic images from actual breast surgery. Viewer discretion is advised.

    Click the chapter icon on the player to search discussion topics.

    David Dabbs, MD

    PreludeDx Chief of Pathology

    0:00 Speaker Introductions & Agenda
    3:23 The Unmet Clinical Need – Individualized DCIS Treatment
    12:32 DCISionRT – Providing Personalized DCIS Information
    14:03 DCISionRT Overview and Data Highlights
    23:50 The Future of DCISionRT

    Julie Reiland, MD, FACS

    Committee Chair, American Society of Breast Surgeons

    26:07 Oncoplastic Surgery & Related Surgical Techniques
    29:53 Surgical Planning with DCISionRT
    31:37 Surgical Videos (Warning: Graphic)
    45:09 Getting Started with Oncoplastic Surgery
    46:33 Conclusion

    Anne Peled, MD

    Co-Director, Sutter CPMC Breast Cancer Program

    48:53 Clinical Application of DCISionRT
    50:54 Case Studies
    56:46 Clinical Considerations & Conclusion

    Q and A with the Panelists

    48:07 How can I integrate DCISionRT with the doctors in my practice?
    51:40 Can DCISionRT be used to help guide endocrine therapy?
    54:52 Is DCISionRT covered by insurance?

  • Will my Breast Cancer Patient with DCIS Benefit from Radiation after Surgery?

    Moderator: Dede Goehler, BSN
    Featured Speaker: Leonard Farber, MD

    Click the chapter icon on the player to search discussion topics.

    Dede Goehler, BSN

    Registered Nurse & PreludeDx Patient Advocate

    0:00 Speaker Introduction

    Leonard Farber, MD

    Radiation Oncologist

    1:54 Speaker Introduction
    2:34 Current Standard of DCIS Care
    3:52 Who Benefits from Radiation Therapy?
    5:50 DCISionRT Overview
    10:31 DCISionRT & OncotypeDx DCIS: A Comparison
    12:09 DCISionRT validation data highlights
    21:47 DCISionRT PREDICT Registry
    22:53 Case Studies
    29:30 Conclusion: A Radiation Oncologist’s Perspective

    Q and A with the Panelists

    32:48 What is the turn-around-time for DCISionRT?
    33:06 Does insurance cover DCISionRT?
    34:44 As a nurse, how can I help integrate DCISionRT into my physician’s practice?
    36:46 What type of tissue specimen can DCISionRT be ordered on?
    39:30 Does DCISionRT account for the benefits of hormone therapy?

  • Real-Time Perspectives and Recommendations for Meaningful Application of DCISionRT in Your Surgical Practice

    Presented by: Troy Bremer, Ph.D. and Vincent Reid, MD, FACS

    Click the chapter icon on the player to search discussion topics.

    Troy Bremer, Ph.D.

    CSO and Founder of PreludeDx

    0:29 Current Standard of DCIS Care
    1:07 Role of Radiation Therapy for DCIS
    3:12 DCISionRT Overview & Test Results Explanation
    5:04 DCISionRT Validation Data Highlights
    16:24 DCISionRT: Consistent RT Prediction
    18:58 DCISionRT Clinical Summary
    20:09 PREDICT Registry Summary
    21:06 Future of DCISionRT

    Vincent Reid, MD, FACS

    Medical Director, Hall-Perrine Cancer Center & Chairman of Surgery, Mercy Medical Center

    22:46 Speaker Introduction
    23:45 Clinical Dilemma for Managing DCIS Patients
    26:45 Case Studies
    33:50 Conclusion: A Surgeon’s Perspective

    Q and A with the Panelists

    36:19 What does a DCISion Score of 3 mean for a patient?
    37:30 Is DCISionRT covered by insurance?
    38:11 How does DCISionRT work in different subtypes of patients?
    40:17 How to incorporate DCISionRT into protocol with tumor boards?
    41:37 Do unexpected recurrences occur in patients tested with DCISionRT?
    42:45 How to best introduce DCISionRT for implementation in a multidisciplinary practice?
    44:36 How does DCISionRT impact mastectomy considerations?
    46:16 How do high DCISion Scores & large lesions impact treatment recommendations?
    47:20 What are benefits of ordering DCISionRT on Pre-Surgical Biopsy Specimen?
    48:23 What is the Turn Around Time?
    48:42 How does DCISionRT help with decision between BCS + RT vs oncoplastic vs mastectomy?

  • Successful Implementation of DCISionRT in your Radiation Oncology Practice for Enhanced DCIS Treatment

    Presented by: Troy Bremer, Ph.D. and Kristina Mirabeau-Beale, MD, MPH

    Click the chapter icon on the player to search discussion topics.

    Troy Bremer, Ph.D.

    CSO and Founder of PreludeDx

    0:00 Speaker Introductions
    1:49 Presentation Agenda
    3:51 Role of Radiation Therapy for DCIS
    7:03 DCISionRT Overview & Test Results Explanation
    9:21 DCISionRT Validation Data Highlight
    20:56 DCISionRT: Consistent RT Prediction
    24:31 DCISionRT Clinical Summary
    25:51 PREDICT Registry Summary
    27:01 Future of DCISionRT
    28:52 Short Q&A

    Kristina Mirabeau-Beale, MD, MPH

    Radiation Oncologist, GenesisCare

    29:48 Clinical Dilemma for Managing DCIS Patients
    31:46 Case Studies
    43:31 Physician Analysis Report
    45:45 Conclusion: Radiation Oncologist’s Perspective

    Q and A with the Panelists

    48:05 Can you order DCISionRT for micro-invasive disease?
    48:38 How does selection bias impact patient referrals to your practice?
    50:35 DCISionRT Insurance Coverage
    52:00 Does DCISionRT address the use of hormone therapy?
    53:14 DCISionRT & NCCN Guidelines

  • The Clinical Impact of Precision Testing on Your DCIS Patient Management

    Presented by: Christy Kesslering, MD, Troy Bremer, Ph.D. and Jim Pellicane, MD

    Click the chapter icon on the player to search discussion topics.

    Troy Bremer, Ph.D.

    CSO and Founder of PreludeDx

    2:00 DCISionRT—Background of Assay, Supporting Evidence/Data, Outcomes

    Jim Pellicane, MD

    • Breast Cancer Surgeon
    • Director of Breast Oncology
    • Bon Secours Cancer Institute
    15:50 Introduction
    16:16 Surgeon’s clinical dilemma to assessing risk in DCIS patients
    22:57 Why is ER not a good indicator of risk assessment?
    24:13 Why is patient age is no an independent predictor of risk?
    25:23 What are side effects of RT, especially for younger patients?
    26:20 What are the surgical options and decisions impacted by RT?
    27:11 Case Studies
    36:00 Personal lessons learned
    39:18 What is the impact of hormone therapy on DCISionRT score?

    Christy Kesslering, MD

    • Radiation Oncologist, Breast Cancer Specialist
    • Radiation Oncology Consultants
    • Northwester Medicine Radiation Oncology, Warrenville
    39:55 Introduction
    40:04 Clinical dilemma: Am I seeing all the patients? When do surgeons refer patients to me?
    50:04 Why Tumor Grade and RTOG9804 Classification is not always the best indicator of Risk?
    51:23 Case Studies
    52:15 Clinical Application of DCISionRT testing for DCIS patients
    53:08 Why should DCISionRT be ordered for every patient?
    55:20 How genomic testing can help guide intensification and de-escalation of RT
    56:52 Challenges and solution insights for radiation oncologists to use genomics in DCIS

    Q and A with the Panelists

    59:22 Why is 0.8 that DCISionRT common score? Answered by Christy
    1:00:46 Turn-around-time and Billing. Answered by Dr. Pellicane
    1:01:43 How do you build consensus/buy-in within your medical group/colleagues to implement a DCIS protocol between radiation oncologists and surgeons? Answered by Dr. Pellicane and Dr. Kesslering
    1:03:20 Why order DCISionRT on all my DCIS patients? Answered by Dr. Kesslering
    1:04:28 What are the results and implications of interaction studies between DCISion Score and RT? Answered by Dr. Bremer
    105:59 Conclusion

  • Predicting Radiation Therapy Benefit with DCISionRT

    Presented by: Troy Bremer, Ph.D., Chirag Shah, MD and Pat Whitworth, MD, FACS

    Click the chapter icon on the player to search discussion topics.

    Troy Bremer, Ph.D.

    CSO and Founder of PreludeDx

    0:46 Supportive evidence for DCISionRT
    2:12 DCISionRT overview and test results
    4:30 Validation data highlights
    7:30 RT benefit prediction and NNT data highlight
    8:14 Reclassification data highlight

    Chirag Shah, MD

    • Radiation Oncologist
    • Director of Clinical Research and Associate Professor
    • Department of Radiation Oncology at the Cleveland Clinic
    8:54 Introduction
    9:07 Managing DCIS and RT role in background studies
    12:30 Who needs or doesn’t need RT?
    14:07 Changing treatment recommendations
    15:51 Applying DCISionRT in my practice
    17:11 Cost effectiveness and value
    18:39 Case Studies
    19:56 Conclusion: Radiation oncologist’s perspectives

    Pat Whitworth, MD

    • Breast Surgical Oncology Specialist
    • St. Thomas Health, Ascension
    • Direction of Nashville Breast Center
    21:06 Introduction
    21:24 Impact of genomic testing in clinical practice, pre-op visit
    22:43 Clinical dilemma for DCIS
    24:33 DCIS tools to guide patient management, pros/cons
    26:54 Surgical margins and guidelines
    28:53 Genomic assays for DCIS
    30:58 Identifying patients with RT benefit after BCS
    31:58 Patient Discussion with DCISionRT Test Report
    32:50 Clinical application and case studies
    36:58 Conclusion: Surgeon’s perspectives
    37:41 Decision impact PREDICT Registry

    Q and A with the Panelists

    38:50 How to interpret DCISionRT in context of ET?
    39:48 Case study recommendation with low DCISionRT
    42:10 Role of MSKCC nomogram for DCIS management?
    43:40 DCISionRT protocol in own medical practices?
    45:35 Role of APBI in DCIS?
    46:48 Which patients are indicated for DCISionRT?

Want to know when our next webinar will be posted?

Enter your email and we’ll put you on our webinar notification list.